scispace - formally typeset
E

Erin E. Chambers

Researcher at Waters Corporation

Publications -  19
Citations -  1109

Erin E. Chambers is an academic researcher from Waters Corporation. The author has contributed to research in topics: Matrix (chemical analysis) & High-performance liquid chromatography. The author has an hindex of 9, co-authored 18 publications receiving 1002 citations.

Papers
More filters
Journal ArticleDOI

Systematic and comprehensive strategy for reducing matrix effects in LC/MS/MS analyses

TL;DR: The combination of polymeric mixed-mode SPE, the appropriate mobile phase pH and UPLC technology provides significant advantages for reducing matrix effects resulting from plasma matrix components and in improving the ruggedness and sensitivity of bioanalytical methods.
Journal ArticleDOI

Performance of plasma free metanephrines measured by liquid chromatography-tandem mass spectrometry in the diagnosis of pheochromocytoma.

TL;DR: Plasma metanephrines measured by LC-MS/MS are a reliable and sensitive test for the biochemical detection of pheochromocytoma.
Journal ArticleDOI

Quantitation of amyloid beta peptides Aβ(1-38), Aβ(1-40), and Aβ(1-42) in human cerebrospinal fluid by ultra-performance liquid chromatography-tandem mass spectrometry.

TL;DR: A mixed-mode solid-phase extraction method and an ultra-performance liquid chromatography tandem mass spectrometry (SPE UPLC-MS/MS) assay for the simultaneous quantitation of amyloid beta peptides from human cerebrospinal fluid (CSF).
Journal ArticleDOI

Improved sensitivity of the nano ultra-high performance liquid chromatography-tandem mass spectrometric analysis of low-concentrated neuropeptides by reducing aspecific adsorption and optimizing the injection solvent.

TL;DR: Since the reduction of peptide adsorption and the optimization of the injection solvent resulted in a clear and quantifiable signal of the three peptides, optimization of both issues should be considered in the early stage of method development, in particular when the analysis of low-concentration peptide solutions is envisaged.